Supiot S, Vaugier L, Pasquier D, et al. - In men with oligorecurrent pelvic node relapses of prostate cancer, a prolonged tumor control appeared to be provided by combined high-dose salvage pelvic radiotherapy and androgen depriving therapy (ADT) with limited toxicity. Complete remission in nearly half of patients was noted after 3 yrs of treatment. Findings demonstrate initial evidence of benefit.

• This is an open-label, phase II trial of 67 patients with oligorecurrent (five or fewer) pelvic node relapses of prostate cancer; half of the patients had received prior prostatic irradiation.

• Patients were administered combined high-dose intensity-modulated radiotherapy and ADT (6 mo).

• Two- and 3-yr progression-free survival rates were 81% and 58%, respectively.

• A median progression-free survival of 45.3 mo and median biochemical relapse–free survival (BRFS) of 25.9 mo was achieved.

• BRFS rates at 2 and 3 yr were 58% and 46%, respectively.

• Grade 2 + 2-yr genitourinary and gastrointestinal toxicities were noted to be 10% and 2%, respectively.